PROCF (Sofgen Pharma) 3-Year EPS without NRI Growth Rate: 0.00% (As of Dec. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PROCF Sofgen Pharma SA PROCF
24 GF Score
Price $0.00
View Full Analysis

What is Sofgen Pharma 3-Year EPS without NRI Growth Rate?

Sofgen Pharma PROCF 24 3-Year EPS without NRI Growth Rate is 0.00% as of Dec. 2024. GuruFocus rates PROCF with a GF Score™ of 24/100.

Sofgen Pharma's EPS without NRI for the three months ended in Dec. 2024 was $0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

Sofgen Pharma  (OTCPK:PROCF) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.

Sofgen Pharma 3-Year EPS without NRI Growth Rate Related Terms

PROCF vs BKUH, ORGO, SIGA: 3-Year EPS without NRI Growth Rate Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Sofgen Pharma's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sofgen Pharma 3-Year EPS without NRI Growth Rate vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sofgen Pharma's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Sofgen Pharma's 3-Year EPS without NRI Growth Rate falls into.


PROCF
24GF Score
Sofgen Pharma SA PROCF
3-Year EPS without NRI Growth Rate is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sofgen Pharma 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

What does a 3-Year EPS without NRI Growth Rate of 0.00% mean?
Sofgen Pharma (PROCF) has a 3-Year EPS without NRI Growth Rate of 0.00% as of Dec. 2024. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Sofgen Pharma and its competitors.
Is Sofgen Pharma's 3-Year EPS without NRI Growth Rate too high?
Sofgen Pharma's current 3-Year EPS without NRI Growth Rate is 0.00%. Overall, Sofgen Pharma has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Sofgen Pharma's 3-Year EPS without NRI Growth Rate compare to BKUH and ORGO?
Sofgen Pharma's 3-Year EPS without NRI Growth Rate of 0.00% can be compared against companies in the Drug Manufacturers industry. The industry median 3-Year EPS without NRI Growth Rate is 9.80. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Drug Manufacturers company?
The median 3-Year EPS without NRI Growth Rate among Drug Manufacturers companies is 9.80, based on 784 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Sofgen Pharma and its competitors. For the Drug Manufacturers industry, the median 3-Year EPS without NRI Growth Rate is 9.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sofgen Pharma's current 3-Year EPS without NRI Growth Rate is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sofgen Pharma stock overvalued right now?
Sofgen Pharma (PROCF) has a current 3-Year EPS without NRI Growth Rate of 0.00%. The current 3-Year EPS without NRI Growth Rate is 0.00%. Sofgen Pharma's overall GF Score™ is 24/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Sofgen Pharma (PROCF), the current 3-Year EPS without NRI Growth Rate is 0.00% as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sofgen Pharma Business Description

Address 9 Rue de Bitbourg, Luxembourg, LUX, L-1273
Procaps Group SA is an integrated healthcare and pharmaceutical company that develops and manufactures pharmaceutical and nutraceutical solutions, medicines, and hospital supplies. The company's segment includes NextGel, Procaps Colombia, CAN, CASAND, and Diabetrics. It generates maximum revenue from the NextGel segment. It has geographic presence in Bolivia, Brazil, Colombia, Costa Rica, Dominican Republic, Ecuador, El Salvador, Guatemala, Honduras, Nicaragua, Panama, Peru, and the United States.
24GF Score

Get the complete analysis for PROCF

3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price